|
1
|
Obertova Z, Brown C, Holmes M and
Lawrenson R: Prostate cancer incidence and mortality in rural men -
a systematic review of the literature. Rural Remote Health.
12:20392012.PubMed/NCBI
|
|
2
|
Armstrong AP, Miller RE, Jones JC, Zhang
J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing
prostate tumor cells and mediates migration and expression of tumor
metastasis genes. Prostate. 68:92–104. 2008. View Article : Google Scholar
|
|
3
|
Buijs JT, Henriquez NV, van Overveld PG,
van der Horst G, ten Dijke P and van der Pluijm G: TGF-beta and
BMP7 interactions in tumour progression and bone metastasis. Clin
Exp Metastasis. 24:609–617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whang PG, Gamradt SC, Gates JJ and
Lieberman JR: Effects of the proteasome inhibitor bortezomib on
osteolytic human prostate cancer cell metastases. Prostate Cancer
Prostatic Dis. 8:327–334. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Satoh F, Mimata H, Nomura T, et al:
Autocrine expression of neurotrophins and their receptors in
prostate cancer. Int J Urol. 8:S28–S34. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Festuccia C, Gravina GL, Muzi P, et al: In
vitro and in vivo effects of bicalutamide on the expression of TrkA
and P75 neurotrophin receptors in prostate carcinoma. Prostate.
67:1255–1264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hellwinkel OJ, Asong LE, Rogmann JP, et
al: Transcription alterations of members of the
ubiquitin-proteasome network in prostate carcinoma. Prostate Cancer
Prostatic Dis. 14:38–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garrett IR, Chen D, Gutierrez G, et al:
Selective inhibitors of the osteoblast proteasome stimulate bone
formation in vivo and in vitro. J Clin Invest. 111:1771–1782. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Micel LN, Tentler JJ, Smith PG and
Eckhardt GS: Role of ubiquitin ligases and the proteasome in
oncogenesis: novel targets for anticancer therapies. J Clin Oncol.
31:1231–1238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang B and Kumar S: Nedd4 and Nedd4-2:
closely related ubiquitin-protein ligases with distinct
physiological functions. Cell Death Differ. 17:68–77. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Farooqi AA, Waseem MS, Riaz AM and Bhatti
S: SMURF and NEDD4: sharp shooters monitor the gate keepers and ion
traffic controllers of lead astray cell. J Membr Biol. 244:1–8.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen C, Sun X, Guo P, et al: Ubiquitin E3
ligase WWP1 as an oncogenic factor in human prostate cancer.
Oncogene. 26:2386–2394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Papandreou CN and Logothetis CJ:
Bortezomib as a potential treatment for prostate cancer. Cancer
Res. 64:5036–5043. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adams J, Palombella VJ, Sausville EA, et
al: Proteasome inhibitors: a novel class of potent and effective
antitumor agents. Cancer Res. 59:2615–2622. 1999.PubMed/NCBI
|
|
15
|
Sunwoo JB, Chen Z, Dong G, et al: Novel
proteasome inhibitor PS-341 inhibits activation of nuclear
factor-kappa B, cell survival, tumor growth, and angiogenesis in
squamous cell carcinoma. Clin Cancer Res. 7:1419–1428.
2001.PubMed/NCBI
|
|
16
|
Williams S, Pettaway C, Song R, Papandreou
C, Logothetis C and McConkey DJ: Differential effects of the
proteasome inhibitor bortezomib on apoptosis and angiogenesis in
human prostate tumor xenografts. Mol Cancer Ther. 2:835–843.
2003.PubMed/NCBI
|
|
17
|
Uy GL, Trivedi R, Peles S, et al:
Bortezomib inhibits osteoclast activity in patients with multiple
myeloma. Clin Lymphoma Myeloma. 7:587–589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oyajobi BO, Garrett IR, Gupta A, et al:
Stimulation of new bone formation by the proteasome inhibitor,
bortezomib: implications for myeloma bone disease. Br J Haematol.
139:434–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giuliani N, Morandi F, Tagliaferri S, et
al: The proteasome inhibitor bortezomib affects osteoblast
differentiation in vitro and in vivo in multiple myeloma patients.
Blood. 110:334–338. 2007. View Article : Google Scholar
|
|
20
|
Alaaeddine N, De Montigny C and Sadouk M:
Real-time reverse transcription-polymerase chain reaction
quantification of tumor necrosis factor alpha messenger in human
leukocytes. Clin Lab. 57:799–802. 2011.
|
|
21
|
Zhu Y, Li T, Song J, et al: The
TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting
IL-1R-mediated MyD88- dependent signaling. Basic Res Cardiol.
106:787–799. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weeraratna AT, Dalrymple SL, Lamb JC, et
al: Pan-trk inhibition decreases metastasis and enhances host
survival in experimental models as a result of its selective
induction of apoptosis of prostate cancer cells. Clin Cancer Res.
7:2237–2245. 2001.
|
|
23
|
Chen C and Matesic LE: The Nedd4-like
family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev.
26:587–604. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rieser E, Cordier SM and Walczak H: Linear
ubiquitination: a newly discovered regulator of cell signalling.
Trends Biochem Sci. 38:94–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bernassola F, Karin M, Ciechanover A and
Melino G: The HECT family of E3 ubiquitin ligases: multiple players
in cancer development. Cancer Cell. 14:10–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murakami G, Watabe T, Takaoka K, Miyazono
K and Imamura T: Cooperative inhibition of bone morphogenetic
protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell.
14:2809–2817. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Severe N, Dieudonne FX and Marie PJ: E3
ubiquitin ligase-mediated regulation of bone formation and
tumorigenesis. Cell Death Dis. 4:e4632013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jones DC, Wein MN, Oukka M, Hofstaetter
JG, Glimcher MJ and Glimcher LH: Regulation of adult bone mass by
the zinc finger adapter protein Schnurri-3. Science. 312:1223–1227.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao L, Huang J, Zhang H, et al: Tumor
necrosis factor inhibits mesenchymal stem cell differentiation into
osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells.
29:1601–1610. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sterz J, von Metzler I, Hahne JC, et al:
The potential of proteasome inhibitors in cancer therapy. Expert
Opin Investig Drugs. 17:879–895. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma MH, Yang HH, Parker K, et al: The
proteasome inhibitor PS-341 markedly enhances sensitivity of
multiple myeloma tumor cells to chemotherapeutic agents. Clin
Cancer Res. 9:1136–1144. 2003.PubMed/NCBI
|
|
32
|
Kane RC, Farrell AT, Sridhara R and Pazdur
R: United States Food and Drug Administration approval summary:
bortezomib for the treatment of progressive multiple myeloma after
one prior therapy. Clin Cancer Res. 12:2955–2960. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiang YW, Hu B, Chen Y, et al: Bortezomib
induces osteoblast differentiation via Wnt-independent activation
of beta-catenin/TCF signaling. Blood. 113:4319–4330. 2009.
View Article : Google Scholar : PubMed/NCBI
|
